Ionis Pharmaceuticals, Inc. Common Stock (IONS) is a publicly traded Healthcare sector company. As of May 21, 2026, IONS trades at $75.44 with a market cap of $11.98B and a P/E ratio of 74.97. IONS moved +1.63% today. Year to date, IONS is -4.42%; over the trailing twelve months it is +117.75%. Its 52-week range spans $23.95 to $86.74. Analyst consensus is strong buy with an average price target of $105.94. Rallies surfaces IONS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tweedy Browne Cuts Ionis Stake Over 40% to 2.1M Shares: Value manager Tweedy Browne cut its Ionis Pharmaceuticals stake by over 40%, reducing holdings from 3.7 million to 2.1 million shares in the latest 13F filing. The repositioning lowered Ionis to roughly 3.8% of the firm’s total equity portfolio.
| Metric | Value |
|---|---|
| Price | $75.44 |
| Market Cap | $11.98B |
| P/E Ratio | 74.97 |
| EPS | $1.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $86.74 |
| 52-Week Low | $23.95 |
| Volume | 473 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.06B |
| Net Income | $154.57M |
| Gross Margin | 98.35% |
17 analysts cover IONS: 0 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $105.94.